Giovanna Borriello

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/873358/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Diseaseâ€Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Annals of Neurology, 2021, 89, 780-789.	5.3	370
2	fMRI evidence of brain reorganization during attention and memory tasks in multiple sclerosis. NeuroImage, 2004, 21, 858-867.	4.2	285
3	Oneâ€year MRI scan predicts clinical response to interferon beta in multiple sclerosis. European Journal of Neurology, 2009, 16, 1202-1209.	3.3	122
4	Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clinical Rehabilitation, 2007, 21, 331-337.	2.2	96
5	DMTs and Covidâ€19 severity in MS: a pooled analysis from Italy and France. Annals of Clinical and Translational Neurology, 2021, 8, 1738-1744.	3.7	86
6	Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 64-71.	3.0	85
7	A Low-Cost Cognitive Rehabilitation With a Commercial Video Game Improves Sustained Attention and Executive Functions in Multiple Sclerosis. Neurorehabilitation and Neural Repair, 2015, 29, 453-461.	2.9	60
8	Natalizumab treatment in pediatric multiple sclerosis: A case report. European Journal of Paediatric Neurology, 2009, 13, 67-71.	1.6	59
9	Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. Multiple Sclerosis Journal, 2013, 19, 1106-1112.	3.0	56
10	Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis. Journal of the Neurological Sciences, 2012, 323, 104-112.	0.6	47
11	COVIDâ€19 pandemic and mental distress in multiple sclerosis: implications for clinical management. European Journal of Neurology, 2020, 28, 3375-3383.	3.3	47
12	Pulse monthly steroids during an elective interruption of natalizumab: a postâ€marketing study. European Journal of Neurology, 2012, 19, 783-787.	3.3	43
13	SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. Multiple Sclerosis Journal, 2022, 28, 1034-1040.	3.0	37
14	Perceived stress and social support in a large population of people with multiple sclerosis recruited online through the COVIDâ€19 pandemic. European Journal of Neurology, 2021, 28, 3396-3402.	3.3	36
15	Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study. CNS Drugs, 2018, 32, 963-970.	5.9	35
16	COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach. Multiple Sclerosis and Related Disorders, 2020, 41, 102165.	2.0	35
17	Observations during an elective interruption of natalizumab treatment: a post-marketing study. Multiple Sclerosis Journal, 2011, 17, 372-375.	3.0	33
18	The Effects of Concurrent Resistance and Aerobic Exercise Training on Functional Status in Patients with Multiple Sclerosis. Current Sports Medicine Reports, 2019, 18, 452-457.	1.2	30

GIOVANNA BORRIELLO

#	Article	IF	CITATIONS
19	Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641879640.	3.5	26
20	Effect of dalfampridine on information processing speed impairment in multiple sclerosis. Neurology, 2019, 93, e733-e746.	1.1	21
21	Mitoxantrone treatment in multiple sclerosis: a 5-year clinical and MRI follow-up. European Journal of Neurology, 2007, 14, 1281-1287.	3.3	20
22	Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience. Journal of Neurology, 2019, 266, 411-416.	3.6	20
23	Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?. BMC Neurology, 2011, 11, 26.	1.8	19
24	Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis. Journal of Neurology, 2020, 267, 3008-3020.	3.6	19
25	Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study. Journal of Neurology, 2021, 268, 2922-2932.	3.6	18
26	Emerging oral drugs for multiple sclerosis. Expert Opinion on Emerging Drugs, 2008, 13, 465-477.	2.4	17
27	MRI-based analysis of the natalizumab therapeutic window in multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 1337-1339.	3.0	15
28	Effects of 2-year treatment with dimethyl fumarate on cognition and functional impairment in patients with relapsing remitting multiple sclerosis. Neurological Sciences, 2020, 41, 3185-3193.	1.9	15
29	Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study. Expert Opinion on Drug Delivery, 2016, 13, 799-805.	5.0	13
30	Physical Exercise Moderates the Effects of Disability on Depression in People with Multiple Sclerosis during the COVID-19 Outbreak. Journal of Clinical Medicine, 2021, 10, 1234.	2.4	10
31	Disability assessment using Google Maps. Neurological Sciences, 2022, 43, 1007-1014.	1.9	10
32	Impact of early diagnosis on clinical characteristics of an Italian sample of people with multiple sclerosis recruited online. Multiple Sclerosis and Related Disorders, 2019, 27, 239-246.	2.0	9
33	Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience. Frontiers in Neurology, 2020, 11, 105.	2.4	8
34	The effect of air pollution on COVIDâ€19 severity in a sample of patients with multiple sclerosis. European Journal of Neurology, 2022, 29, 535-542.	3.3	8
35	Real time PCR for detection of Chlamydophila pneumoniae in peripheral blood mononuclear cells of patients with multiple sclerosis. Journal of Neurology, 2007, 254, 1293-1295.	3.6	6
36	Exit strategies for "needle fatigue―in multiple sclerosis: a propensity score-matched comparison study. Journal of Neurology, 2020, 267, 694-702.	3.6	6

GIOVANNA BORRIELLO

#	Article	IF	CITATIONS
37	Treating multiple sclerosis with fingolimod or intramuscular interferon. Expert Opinion on Pharmacotherapy, 2010, 11, 1957-1960.	1.8	4
38	The clinical value of Coop/Wonca charts in assessment of HRQoL in a large cohort of relapsing-remitting multiple sclerosis patients: Results of a multicenter study. Multiple Sclerosis and Related Disorders, 2017, 17, 154-171.	2.0	4
39	Case Report: Concurrent Resistance and Aerobic Training Regulate Adiponectin Expression and Disease Severity in Multiple Sclerosis: A Case Study. Frontiers in Neuroscience, 2020, 14, 567302.	2.8	4
40	Alopecia Universalis Occurring after Alemtuzumab Treatment for Multiple Sclerosis. A Two-Year Follow-Up of Two Patients. International Journal of Environmental Research and Public Health, 2021, 18, 7338.	2.6	4
41	Cesarean section in women with MS: A choice or a need?. Multiple Sclerosis and Related Disorders, 2020, 38, 101867.	2.0	3
42	Long-term fingolimod treatment in two pediatric patients with multiple sclerosis. Neurological Sciences, 2021, 42, 29-36.	1.9	1
43	Why physical activity improves quality of life in multiple sclerosis patients: correlation between fatigue and functional parameters. Medicina Dello Sport, 2019, 72, .	0.1	1
44	Effects of an unconventional re-walking training on physical, psychological, and cognitive impairment in multiple sclerosis patients. Medicina Dello Sport, 2018, 71, .	0.1	1